OncoMatch/Clinical Trials/NCT04988945
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
Is NCT04988945 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Durvalumab and Tremelimumab for hcc.
Treatment: Durvalumab · Tremelimumab — This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and stereotactic body radiotherapy (SBRT) with immune checkpoint inhibitors in unresectable hepatocellular carcinoma (HCC) patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy
No prior immunotherapy
Cannot have received: radiation therapy
Exception: prior radiotherapy to the region of liver or selective internal radiotherapy
Prior radiotherapy to the region of liver or selective internal radiotherapy
Cannot have received: anti-PD-1 therapy
Patients who have received prior anti-PD-1, anti-PD-L1 or anti-CTLA-4
Cannot have received: anti-PD-L1 therapy
Patients who have received prior anti-PD-1, anti-PD-L1 or anti-CTLA-4
Cannot have received: anti-CTLA-4 therapy
Patients who have received prior anti-PD-1, anti-PD-L1 or anti-CTLA-4
Lab requirements
Blood counts
Haemoglobin ≥ 9.0 g/dL; ANC ≥1.5 (or 1.0) x (> 1500 per mm^3); Platelet count ≥ 75 x 10^9/L (>75,000 per mm^3)
Kidney function
Measured creatinine clearance (CL) >45 mL/min or Calculated creatinine clearance CL>45 mL/min by Cockcroft-Gault formula or by 24-hour urine collection
Liver function
Serum bilirubin ≤1.5 x institutional ULN; AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN; Child-Pugh liver function class A-B7
Adequate normal organ and marrow function as defined below: Haemoglobin ≥ 9.0 g/dL; ANC ≥1.5 (or 1.0) x (> 1500 per mm^3); Platelet count ≥ 75 x 10^9/L (>75,000 per mm^3); Serum bilirubin ≤1.5 x institutional ULN; AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN; Measured creatinine clearance (CL) >45 mL/min or Calculated creatinine clearance CL>45 mL/min by Cockcroft-Gault formula or by 24-hour urine collection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify